Trial · NCT06632405
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall response rate (ORR) | from the first drug administration up to the first occurrence of progression or death （up to 36 weeks） | The propotion of subjects with CR or PR. |
| Secondary | Adverse events/Serious adverse events | from the first drug administration to within 90 days for the last dose | Adverse events/Serious adverse events |
| Secondary | Disease Control Rate (DCR) | from the first drug administration up to the first occurrence of progression or death （up to 36 weeks） | The propotion of subjects with CR, PR, or SD. |
| Secondary | Clinical benefit rate (CBR) | propotion of subjects with CR, PR, or SD for >=6 months （up to 36 weeks） | The propotion of subjects with CR, PR, or SD for \>=6 months during the study |
| Secondary | Duration of response (DoR) | from the first drug administration up to the first occurrence of progression or death （up to 36 weeks） | The time from randomization to disease progression or death for patients who achieve complete or partial alleviation |
| Secondary | Time to response (TTR) | from the first drug administration up to the first occurrence of progression （up to 36 weeks） | Time from date of first dose to date of first occurrence of response |
| Secondary | Progression-Free-Survival (PFS) | from the first drug administration up to the first occurrence of progression or death （up to 36 weeks） | from the first drug administration up to the first occurrence of progression or death (up to 24 months) |
| Secondary | Overall survival (OS) | 12 months after the first drug administration | 12 months after the first drug administration |
| Secondary | Biomarkers | pre-treatment, up to 24 months | Compare the change of biomarkers from urine, blood or tissues, such as the carcinoembryonic antigen (ug/L), before or after the treatments. |
| Secondary | Biomarkers | pre-treatment, up to 24 months | Compare the change of biomarkers from urine, blood or tissues, such as the CA125/199/153(u/ml), before or after the treatments. |
| Secondary | patient reported outcomes (PRO) | during the study and up to 36 weeks after the end | direct reports from patients about their health, the scale Quality of Life questionnaire (QLQ)-BR23/C30 will be used for assecessment. Higher score indicate better life quality |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06632405/registered